12:00 AM
 | 
Feb 06, 2012
 |  BC Week In Review  |  Company News  |  Deals

Sangamo, Shire deal

Sangamo granted Shire exclusive, worldwide rights to zinc finger DNA-binding protein (ZFP) therapeutics targeting four genes - Factors VII, VIII, IX and X. Shire plans to develop...

Read the full 115 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >